Skip to main content
. 2019 Jun 12;7(1):e000690. doi: 10.1136/bmjdrc-2019-000690

Table 2.

Differences in study variables according to neuropathy status among participants with type 2 DM

Variable Neuropathy status
Nociceptive ( score 12,n = 117 ) Unclear neuropathy (score 13 19,n = 58 ) Neuropathy ( score 19,n = 64 ) P value *
Age (year) 55.41±8.26† 59.79±9.27†‡ 55.55±9.57‡ <0.01
Gender
Male 59 (50.4) 25 (43.1) 15 (23.4) <0.01
Female 58 (49.6) 33 (56.9) 49 (76.6)
BMI (kg/m2) 30.42±3.94 31.17±5.14 31.95±4.44 0.08
Smoking
 Yes 21 (17.9) 11 (19) 11 (17.2) 0.97
 No 96 (82.1) 47 (81) 53 (82.8)
Duration of DM (year) 6 (2–10) 6.5 (4–10) 6 (3–11) 0.62
FBG (mmol/L) 8.6 (6.6–12.28) 8.5 (6.98–11.05) 8.5 (6–13.05) 0.91
HbA1c (%) 7.68 (6.79–9.20) 7.59 (6.84–9.48) 8.02 (6.77–9.64) 0.79
SBP (mm Hg) 138.67±18.08 139.67±17.41 135±13.38 0.25
DBP (mm Hg) 83.75±10.52 82.43±11.11 82.03±8.79 0.51
25-hydroxyvitamin D (ng/mL) 14.34 (8.86–21.65) 15.58 (8.29–25.73) 13.77 (7.43–23.85) 0.83
Vitamin D status
Deficient (<20 ng/mL) 82 (70.1) 36 (62.1) 44 (68.8) 0.55
Insufficient (20–30 ng/mL) 22 (18.8) 17 (29.3) 12 (18.8)
Sufficient (>30 ng/mL) 13 (11.1) 5 (8.6) 8 (12.5)
On neuropathic pain medication (Gabapentin)
Yes 5 (4.3) 6 (10.3) 5 (7.8) 0.26
No 112 (95.7) 52 (89.7) 59 (92.2)

*Statistically significant differences (p<0.05) were determined using one way analysis of variance test with post hoc analysis or Kruskal-Wallis H test for continuous variables and χ2 test or Fisher’s exact test for categorical variables. Data were expressed as frequency (%), mean±SD or median (25th–75th percentiles). Neuropathy status was determined using PainDETECT questionnaire.21

†Post-hoc analysis revealed significant difference in age between nociceptive and unclear neuropathy groups.

‡Post-hoc analysis revealed significant difference in age between unclear neuropathy and neuropathy groups.

BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; SBP, systolic blood pressure.